Targeting macrophage to myofibroblast transition by circ_0001103 for subretinal fibrosis treatment

Qi Zhang1,2, Bing Lu3, Lei He4

  • 1Department of Ophthalmology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, 241001, Anhui, People's Republic of China.

PubMed
Abstract

Insights

Circular RNA circ_0001103 promotes subretinal fibrosis by regulating macrophage-to-myofibroblast transition (MMT). Inhibiting circ_0001103 suppresses fibrosis and leakage in age-related macular degeneration models.

Area of Science:

  • Ophthalmology
  • Molecular Biology
  • Cell Biology

Background:

  • Subretinal fibrosis is a key cause of vision loss in age-related macular degeneration (AMD).
  • The precise mechanisms driving subretinal fibrosis remain incompletely understood.
  • Macrophage-to-myofibroblast transition (MMT) is implicated in fibrotic processes.

Purpose of the Study:

  • To investigate the role of MMT in subretinal fibrosis development.
  • To determine if circ_0001103 regulates subretinal fibrosis formation via MMT.

Main Methods:

  • Established a laser-induced subretinal fibrosis and choroidal neovascularization (CNV) mouse model.
  • Utilized microarray analysis to identify altered circRNAs.
  • Employed immunohistochemistry, dual-luciferase reporter assays, FISH, RNA immunoprecipitation, qRT-PCR, and western blot to analyze molecular interactions and MMT.
  • Intervened with circ_0001103 via intravitreal injection to assess functional effects.

Main Results:

  • Identified 58 significantly altered circRNAs in the CNV mouse model.
  • Observed increased expression of circ_0001103 in MMT and subretinal fibrosis.
  • Demonstrated that circ_0001103 sponges miR-7240-5p, targeting SLC9A to modulate MMT.
  • Showed that inhibiting circ_0001103 suppressed MMT, subretinal fibrosis, and CNV leakage.

Conclusions:

  • circ_0001103 promotes subretinal fibrosis and CNV leakage by regulating SLC9A1-mediated MMT.
  • Inhibition of circ_0001103 offers a potential therapeutic strategy for AMD-related vision loss.